Phase IIIa clinical trials reported more patients achieving target HbA1c with Novo Nordisk’s insulin compared to its once-daily counterparts.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,